Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213682 | 0.82 | NPC1 (0.36) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL407650 | 0.81 | POLB (0.39) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL19818391 | 0.78 | NPC1 (0.34) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL104309 | 0.73 | CHRM2 (0.50) | NPC1RAB9APOLBL3MBTL1 | |
| SCHEMBL459430 | 0.73 | CHRM2 (0.36) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL20376042 | 0.71 | — | — | |
| SCHEMBL13541827 | 0.71 | GFER (0.35) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL13541829 | 0.71 | ALDH1A1 (0.42) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL19395990 | 0.71 | TAAR1 (0.41) | POLBL3MBTL1 | |
| SCHEMBL12304039 | 0.71 | NPC1 (0.35) | NPC1RAB9APOLBL3MBTL1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072600-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072600-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | NPC1 3575/4885RAB9A 4510/4885POLB 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.